SurModics Ebit Over Time
| SRDX Stock | USD 39.56 0.23 0.58% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out SurModics Performance and SurModics Correlation. SurModics |
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of SurModics. If investors know SurModics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about SurModics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 4.358 | Earnings Share (0.82) | Revenue Per Share 8.908 | Quarterly Revenue Growth 0.188 | Return On Assets (0.01) |
The market value of SurModics is measured differently than its book value, which is the value of SurModics that is recorded on the company's balance sheet. Investors also form their own opinion of SurModics' value that differs from its market value or its book value, called intrinsic value, which is SurModics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because SurModics' market value can be influenced by many factors that don't directly affect SurModics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between SurModics' value and its price as these two are different measures arrived at by different means. Investors typically determine if SurModics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, SurModics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Ebit Analysis
Compare SurModics and related stocks such as ProSomnus, Common Stock, LivaNova PLC, and Electromed Ebit Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LIVN | (5.9 M) | 56.5 M | 75.4 M | 87.3 M | 106 M | (51.2 M) | 158.4 M | 128.3 M | 86.3 M | 48 M | (307.2 M) | (74.3 M) | (26.9 M) | (21.8 M) | (20.7 M) |
| ELMD | 359 K | 614.7 K | (1.8 M) | (728.2 K) | 1.3 M | 3.1 M | 3.6 M | 3 M | 2.8 M | 5.1 M | 3.1 M | 3 M | 4 M | 6.6 M | 6.9 M |
| KIDS | (7.2 M) | (7.2 M) | (7.2 M) | (7.2 M) | (7.2 M) | (6.6 M) | (5.1 M) | (6.4 M) | (9.8 M) | (9.1 M) | (30.3 M) | (17.9 M) | (21 M) | (25.8 M) | (24.5 M) |
| NPCE | (22 M) | (22 M) | (22 M) | (22 M) | (22 M) | (22 M) | (22 M) | (22 M) | (22 M) | (22 M) | (12.8 M) | (28.7 M) | (39.6 M) | (24.4 M) | (25.7 M) |
| INGN | (1.6 M) | (1.6 M) | 927 K | 4.5 M | (1.6 M) | 14.7 M | 9.2 M | 17.4 M | 37.9 M | 6 M | (12 M) | 9.2 M | (48.5 M) | (63.8 M) | (60.6 M) |
| LUNG | (942.3 K) | (942.3 K) | (942.3 K) | (942.3 K) | (1.7 M) | (2.5 M) | (2.5 M) | (5.2 M) | (15.9 M) | (17.8 M) | (28.8 M) | (49.8 M) | (60 M) | (57 M) | (54.2 M) |
| APYX | (276.8 K) | (6 K) | 1 M | (3.2 M) | (5.8 M) | (7 M) | (3.8 M) | (4.4 M) | (13.7 M) | (20.9 M) | (19.4 M) | (14.8 M) | (22.9 M) | (18.8 M) | (17.9 M) |
| CNMD | 1.4 M | 68.6 M | 65.2 M | 56.5 M | 52.8 M | 51.2 M | 34.7 M | 46.9 M | 71.3 M | 1.6 M | 61.3 M | 108.6 M | (42 M) | 130.8 M | 137.3 M |
| SIBN | (10.7 M) | (10.7 M) | (10.7 M) | (5.3 M) | (26.3 M) | (26.4 M) | (17.3 M) | (16.8 M) | (12 M) | (36 M) | (37.6 M) | (51.7 M) | (58.4 M) | (39.9 M) | (41.9 M) |
| AXGN | 100 K | (7 M) | (7.8 M) | (9.6 M) | (9.8 M) | (9.2 M) | (8.1 M) | (8 M) | (20.5 M) | (31.4 M) | (22.7 M) | (25.6 M) | (28.3 M) | (18.9 M) | (17.9 M) |
| ANIK | (1.9 M) | 14 M | 20.3 M | 27.3 M | 61.4 M | 48.1 M | 50.6 M | 45.7 M | 21.7 M | 34.2 M | (27.8 M) | (13.4 M) | (19.4 M) | (11.7 M) | (11.1 M) |
| OFIX | 20.9 M | 89 M | 91 M | 59.2 M | 48.4 M | 6.5 M | 18.6 M | 15.7 M | 17.6 M | 24.9 M | 2.1 M | (11.7 M) | (16.4 M) | (140 M) | (133 M) |
| FNA | 2.7 M | 2.7 M | 2.7 M | 2.7 M | 2.7 M | 2.7 M | 2.7 M | 2.7 M | 2.7 M | 2.7 M | 5.6 M | (11.3 M) | (61.6 M) | (37.3 M) | (35.4 M) |
| ITGR | 11.1 M | 14 M | (21.5 M) | 24.8 M | 39 M | (30.2 M) | 113.3 M | 151.5 M | 162.3 M | 158.2 M | 120.4 M | 125.7 M | 113.6 M | 157.7 M | 165.6 M |
| SGHT | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (24 M) | (32.8 M) | (58.4 M) | (81.7 M) | (50 M) | (52.5 M) |
SurModics and related stocks such as ProSomnus, Common Stock, LivaNova PLC, and Electromed Ebit description
My Equities
My Current Equities and Potential Positions
| SurModics | SRDX |
Specialization | Health Care, Health Care Equipment & Services |
| Location | Minnesota; U.S.A |
| Exchange | NASDAQ Exchange |
USD 39.56
Additional Tools for SurModics Stock Analysis
When running SurModics' price analysis, check to measure SurModics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SurModics is operating at the current time. Most of SurModics' value examination focuses on studying past and present price action to predict the probability of SurModics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SurModics' price. Additionally, you may evaluate how the addition of SurModics to your portfolios can decrease your overall portfolio volatility.